Helper T‐cell responses and pulmonary fungal infections

<jats:title>Summary</jats:title><jats:p>The mucosal surface of the respiratory tract encounters microbes, such as fungal particles, with every inhaled breath. When pathogenic fungi breach the physical barrier and innate immune system within the lung to establish an infection, adaptive immunity is engaged, often in the form of helper CD4 T‐cell responses. Type 1 responses, characterized by interferon‐<jats:italic>γ</jats:italic> production from CD4 cells, promote clearance of <jats:italic>Histoplasma capsulatum</jats:italic> and <jats:italic>Cryptococcus neoformans</jats:italic> infection. Likewise, interleukin‐17A (IL‐17A) production from Th17 cells promotes immunity to <jats:italic>Blastomyces dermatitidis</jats:italic> and <jats:italic>Coccidioides</jats:italic> species infection by recruiting neutrophils. In contrast the development of T helper type 2 responses, characterized by IL‐5 production from T cells and eosinophil influx into the lungs, drives allergic bronchopulmonary aspergillosis and poor outcomes during <jats:italic>C. neoformans</jats:italic> infection. Experimental vaccines against several endemic mycoses, including <jats:italic>Histoplasma capsulatum</jats:italic>,<jats:italic> Coccidioides</jats:italic>,<jats:italic> Cryptococcus</jats:italic> and <jats:italic>Blastomyces dermatitidis</jats:italic>, induce protective T‐cell responses and foreshadow the development of vaccines against pulmonary fungal infections for use in humans. Additionally, recent work using antifungal T cells as immunotherapy to protect immune‐compromised patients from opportunist fungal infections also shows great promise. This review covers the role of T‐cell responses in driving protection and pathology in response to pulmonary fungal infections, and highlights promising therapeutic applications of antifungal T cells.</jats:p>